Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza
Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza
复制标题
COVID-19 或 H1N1 流感患者肠道微生物群的变化。
DOI：
10.1093/cid/ciaa709
复制
发表时间：
2020-11-15
影响因子：
11.8
通讯作者：
Li, Lanjuan
中科院分区：
文献类型：
--
作者：
Gu, Silan;Chen, Yanfei;Li, Lanjuan
背景。2019冠状病毒病（COVID-19）是一个新出现的严重全球卫生问题。新冠肺炎患者常见胃肠道症状，粪便标本中检测到严重急性呼吸综合征冠状病毒2 RNA。然而，肠道微生物群与疾病之间的关系仍有待确定。我们对30例COVID- 19患者、24例甲型H1N1流感患者和30例匹配的健康对照（hc）进行了横断面研究，通过16S核糖体RNA基因V3-V4区测序来确定肠道微生物群的差异。与hc患者相比，COVID-19患者细菌多样性明显降低；机会致病菌的相对丰度明显较高，如链球菌、罗氏菌、细孔菌和放线菌；有益共生体的相对丰度较低。5种生物标志物在区分COVID-19患者和hcc方面具有较高的准确性，曲线下面积（AUC）高达0.89。与COVID-19患者相比，H1N1患者表现出较低的多样性和不同的总体微生物组成。选择7个生物标志物来区分两个队列（AUC = 0.94）。COVID-19患者的肠道微生物特征与H1N1患者和hc患者不同。我们的研究表明，肠道微生物群作为COVID-19的诊断生物标志物和治疗靶点的潜在价值，但需要进一步验证。
Background. Coronavirus disease 2019 (COVID-19) is an emerging serious global health problem. Gastrointestinal symptoms are common in COVID-19 patients, and severe acute respiratory syndrome coronavirus 2 RNA has been detected in stool specimens. However, the relationship between the gut microbiome and disease remains to be established.Methods. We conducted a cross-sectional study of 30 patients with COVID- 19, 24 patients with influenza A(H1N1), and 30 matched healthy controls (HCs) to identify differences in the gut microbiota by 16S ribosomal RNA gene V3-V4 region sequencing.Results. Compared with HCs, COVID-19 patients had significantly reduced bacterial diversity; a significantly higher relative abundance of opportunistic pathogens, such as Streptococcus, Rothia, Veillonella, and Actinomyces; and a lower relative abundance of beneficial symbionts. Five biomarkers showed high accuracy for distinguishing COVID-19 patients from HCs with an area under the curve (AUC) up to 0.89. Patients with H1N1 displayed lower diversity and different overall microbial composition compared with COVID-19 patients. Seven biomarkers were selected to distinguish the 2 cohorts (AUC = 0.94).Conclusions. The gut microbial signature of patients with COVID-19 was different from that of H1N1 patients and HCs. Our study suggests the potential value of the gut microbiota as a diagnostic biomarker and therapeutic target for COVID-19, but further validation is needed.